-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3955 Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project

Lymphoma: Chemotherapy, excluding Pre-Clinical Models
Program: Oral and Poster Abstracts
Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster III
Monday, December 7, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Carlos Montalbán, MD PhD1*, Antonio Díaz-López, PhD2*, Heidys Garrote Santana, MD2*, Julián Matias Freue, MD2*, Lourdes López, MD2*, Raquel De Oña, MD1*, Ana M Martín Moreno, PhD2*, Armando López-Guillermo3, Ivan Dlouhi3*, Jordina Rovira3*, Mario Rodríguez4*, José Maria Sánchez Pina4*, Sara Alonso, MD5*, Alejandro Martín García, MD PhD6*, Silvana Novelli, MD7*, Juan-Manuel Sancho8*, Olga García8*, Antonio Salar, MD, PhD9*, Antonio Gutierrez, MD, PhD10, Mariana Bastos11*, Maria Rodriguez-Salazar, MD, PhD12*, Ruben Fernández13*, Juan F. Domínguez14*, Jose A. Queizán15*, Sonia González de Villambrosia16*, Raúl Córdoba17*, Victor Abraira18*, Jose Rodríguez, MD1* and Juan F. Garcia, MD PhD2,19*

1Hematology, MD Anderson Cancer Center Madrid, Madrid, Spain
2Translational Research, MD Anderson Cancer Center, Madrid, Madrid, Spain
3Hematology, Hospital Clinic, Barcelona, Spain
4Hematology, 12 de Octubre Hospital, Madrid, Spain
5Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
6Hematology, Salamanca Hospital, Salamanca, Spain
7Hospital Universitario Sant Pau, Barcelona, Spain
8Servicio de Hematologia, Hospital Germans Trias i Pujol, Badalona, Spain
9Hospital del Mar, Barcelona, Spain
10Hematology, Hospital Son Espases, Palma de Mallorca, Spain
11Hematology, Gregorio Marañon Hospital, Madrid, Spain
12Canary Islands Universitiy Hospital, Santa Cruz de Tenerife, Spain
13Hematology, Cabueñes Hospital, Gijón, Spain
14Hematology, Virgen del Rocio Hospital, Seville, Spain
15Hematology, Segovia Hospital, Segovia, Spain
16Marques de Valdecilla Hospital, Santander, Spain
17Fundación Jiménez-Díaz Hospital, Madrid, Spain
18Ramon y Cajal Hospital Fundation, Madrid, Spain
19Pathology, MD Anderson Cancer Center Madrid, Madrid, Spain

The development of the NCCN International Prognostic Index (NCCN-IPI) for patients with DLBCL treated in the rituximab era improves discrimination when compared to the original IPI model.  The aim of the present study is to validate the results of the NCCN-IPI in a large independent series of patients in a different geographical area.

Materials & Methods. This nation-wide retrospective study includes 2156 patients with de novo DLBCL diagnosed in 20 (mostly) large academic Spanish centers within the Grupo Español de Linfomas  y Transplante de Médula Osea (GELTAMO) network  between 1998 to July 2014. Patients had to be 18 years-old, treated with rituximab plus chemotherapy (R-CHOP or variants and also more intense treatments) and a minimum of 1 year of follow-up; all histological subtypes of DLBCL and primary extranodal cases were acceptable, with the only exclusion of primary testicular or CNS sites.  In the whole series the scoring of the IPI and NCCN-IPI indexes were used and 5-year Overall Survival (5y-OS) estimated with the Kaplan-Meier method and compared with the log-rank test.

Results. Debugging the database resulted in a final working series that included 1885 patients. The demographics of the series were comparable to the NCCN series: NCCN/GELTAMO male gender(%) 54 vs 50.4, Age(y) 57 vs 60, LDH>1(%) 50 vs 54.7, Ann Arbor stage III-IV (%) 59 vs 62.5, ECOG PS≥2(%) 11 vs 30, extranodal disease(%) 36 vs 40.7. The IPI scoring (1760 patients) significantly separated the four risk groups, low (LR, 33.6% of the patients), low/intermediate (LI, 22.7%), intermediate/high (HI, 25.1%) and high (HR, 18.6%) with significantly different (p<0.001 in the global and pairwise comparisons) 5y-OS 5 (88, 77, 68 and 51%, respectively) (Figure 1). The NCCN-IPI (1773 patients) also significantly (p<0.001 in the global and pairwise comparisons) separated the four risk groups (L 12,7%, LI 34.5%, HI 37% and H 15.8%) with 5y-OS (%) of 93, 84, 67 and 49, respectively (Figure 2), comparably to the published data (Table 1). 

Conclusions. NCCN-IPI for the prognosis of DLBC lymphoma treated with chemo-immunotherapy has been validated in a large independent Spanish series. However, in our population the  NCCN-IPI is not more powerful than the IPI for predicting survival.

 

Descripción: \\hospiten\Datos MD ANDERSON\Fundación\Laboratorio Investigacion Traslacional\Antonio Díaz López\NCCN-IPI\Final 29-07-15\Graficas Carlos\29_7\IPINCCN_m.tifDescripción: \\hospiten\Datos MD ANDERSON\Fundación\Laboratorio Investigacion Traslacional\Antonio Díaz López\NCCN-IPI\Final 29-07-15\Graficas Carlos\29_7\IPIoriginal_todos_m.tif

 

 

Disclosures: López-Guillermo: Roche, Celgene, Mundipharma, Gilead, Novartis: Membership on an entity’s Board of Directors or advisory committees , Research Funding . Dlouhi: Gilead: Equity Ownership . Martín García: Servier, Gilead: Consultancy . Sancho: CELLTRION, Inc.: Research Funding .

*signifies non-member of ASH